Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Queensland Health
Healthtrust
Federal Trade Commission
Cipla
Daiichi Sankyo
Baxter
Colorcon

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,399,036

« Back to Dashboard

Which drugs does patent 9,399,036 protect, and when does it expire?

Patent 9,399,036 protects MITIGARE and is included in one NDA.
Summary for Patent: 9,399,036
Title:Methods of colchicine administration
Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
Inventor(s): Ducharme; Murray (St. Laurent, CA)
Assignee: Hikma Pharmaceuticals LLC (Amman, JO)
Application Number:14/566,412
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,399,036
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,399,036

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hikma Intl Pharms MITIGARE colchicine CAPSULE;ORAL 204820-001 Sep 26, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,399,036

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,675,613 Methods of colchicine administration ➤ Try a Free Trial
8,927,607 Methods of colchicine administration ➤ Try a Free Trial
9,789,108 Methods of colchicine administration ➤ Try a Free Trial
9,555,029 Methods of colchicine administration ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Medtronic
Daiichi Sankyo
Healthtrust
Federal Trade Commission
Teva
AstraZeneca
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.